Business Wire

GE Healthcare: DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis and Clinical Management of Patients with Clinically Uncertain ...

NEW ORLEANS, La.-- (BUSINESS WIRE)--GE Healthcare today presented the results of a randomized study analyzing the effect of DaTscan™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...
Medscape

FDA Approves DaTscan for Imaging of Dopamine Transporters

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...
The American Journal of Managed Care

Effective and Efficient Diagnosis of Parkinsonism: The Role of Dopamine Transporter SPECT Imaging With Ioflupane I-123 Injection (DaTscanâ„¢)

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...
TMCnet

SHINE Completes Acquisition of Lantheus SPECT Business, Names Michael Rossi SHINE SPECT CEO

To lead the integration and growth of the SPECT business, SHINE has named Michael Rossi as CEO of SHINE SPECT USA, LLC.
AFP

GE HealthCare announces CE Mark for new digital 4D SPECT/CT system, StarGuide GX

GE HealthCare today announced CE Mark for its new StarGuide™ GX system, i a new digital 4D SPECT/CT designed with excellent precision, clinical efficiency and impressive versatility. This milestone ...